Sickle-Cell Treatment Created With Gene Editing Wins U.K. Approval
Published
Regulators in Britain on Thursday approved the first treatment derived from CRISPR, the revolutionary gene-editing method. Called Casgevy, the treatment is intended to cure sickle-cell disease and a related condition, beta thalassemia. The manufacturers, Vertex Pharmaceuticals, based in Boston,…
#crispr #boston #crisprtherapeutics #switzerland #fda #somerville #mass